The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A double-blind randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated advanced urothelial cancer.
Toni K. Choueiri
No relevant relationships to disclose
Ulka N. Vaishampayan
No relevant relationships to disclose
Evan Y. Yu
No relevant relationships to disclose
David I. Quinn
No relevant relationships to disclose
Noah M. Hahn
No relevant relationships to disclose
Thomas E. Hutson
No relevant relationships to disclose
Robert W. Ross
No relevant relationships to disclose
Jonathan E. Rosenberg
No relevant relationships to disclose
Susanna J. Jacobus
No relevant relationships to disclose
Philip W. Kantoff
No relevant relationships to disclose